News: Articles and Publications

Gates MRI’s CEO Emilio Emini gave an in-depth interview to the Progress, Potential, and Possibilities podcast on immunology, vaccinology, and his career in public health. He also provided an overview of Gates MRI’s research priorities and discussed a call-to-action for preparedness ahead of the next pandemic.

Gates MRI’s Exploratory Biomarker Leader, Nicole Frahm, and Clinical Development Leader, David Holtzman, contributed to the important review of new TB treatment monitoring biomarkers with colleagues from UNITE4TB and FIND — the global alliance for diagnostics.

Gates MRI’s Clinical Development Leader, Alemnew Dagnew, gave an interview about the latest tuberculosis vaccine study at Gates MRI and the future of tuberculosis worldwide.

Gates MRI’s Head of Bioassay Development and Operations, Joleen T. White, published research that provides a hypothetical case study to present an immunogenicity risk assessment for a multi-specific therapeutic as part of an Investigational New Drug (IND) application.

Gates MRI’s Chief Medical Officer and Head of Development, Michael Dunne; Program Lead Mohamed Bassyouni; Head of Global Regulatory Strategy & Operations, Taryn Rogalski-Salter; Head of Translational Discovery, Jared Silverman; and Program Leads Jeroen Medema and Mohamed Bassiouni investigated whether rivaroxaban, a direct oral anticoagulant factor Xa inhibitor, would reduce coronavirus disease 2019 (COVID-19) progression. 

Gates MRI’s Research Project Manager, Judith Maxwell Silverman, contributed to research demonstrating how a bioengineered yeast production strain combined with an optimized version of the SARS-CoV-2 spike protein receptor-binding domain (RBD) exhibits improved biomolecular attributes that are well-suited for further development for large-volume manufacturing of low-cost vaccine candidate.